Biovitrum AB completed its second acquisition of the year, agreeing to a cash and share takeover of fellow Swedish firm Arexis AB. (BioWorld International)
Biovitrum AB completed its second acquisition of the year, agreeing to a cash and share takeover of fellow Swedish firm Arexis AB. (BioWorld International)
NeuroSearch's shares crashed more than 40 percent Aug. 10 on news that its lead drug candidate, NS2330, failed to achieve efficacy in two Phase IIb trials for Parkinson's disease and a third Phase IIb trial for Alzheimer's disease, dashing hopes that the compound would move into Phase III. (BioWorld International)
Santhera Pharmaceuticals AG licensed to Takeda the European rights to its Friedreich's Ataxia (FRDA) treatment, idebenone, in a deal which earned it an up-front payment of EUR5 million (US$6.2 million). (BioWorld International)
Santhera Pharmaceuticals AG licensed to Takeda the European rights to its Friedreich's Ataxia (FRDA) treatment, idebenone, in a deal which earned it an up-front payment of EUR5 million (US$6.2 million). (BioWorld International)
